EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of a Novel Biomarker Panel for Breast Cancer Screening

Maria Vaida, Kamala K Arumalla, Pavan Kumar Tatikonda, Bharadwaj Popuri iD, Rashid A Bux, Paramjit S Tappia iD, Guoyu Huang iD, Jean-François Haince iD, W Randolph Ford

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252111835 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Maria Vaida und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Analytics, Harrisburg University of Science and Technology, Harrisburg, PA 17101, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Biomarkers, Tumor, Early Detection of Cancer, Metabolomics. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biomark Diagnostics Inc. (Richmond, BC, Canada), Maunders-McNeil Foundation (Ed-monton, AB, Canada), BioMark Diagnostics Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer remains a major public health concern, and early detection is crucial for improving survival rates. Metabolomics offers the potential to develop non-invasive screening and diagnostic tools based on metabolic biomarkers. However, the inherent complexity of metabolomic datasets and the high dimensionality of biomarkers complicates the identification of diagnostically relevant features, with multiple studies demonstrating limited consensus on the specific metabolites involved. Unlike previous studies that rely on singular feature selection techniques such as Partial Least Square (PLS) or LASSO regression, this research combines supervised and unsupervised machine learning methods with random sampling strategies, offering a more robust and interpretable approach to feature selection. This study aimed to identify a parsimonious and robust set of biomarkers for breast cancer diagnosis using metabolomics data. Plasma samples from 185 breast cancer patients and 53 controls (from the Cooperative Human Tissue Network, USA) were analyzed. This study also overcomes the common issue of dataset imbalance by using propensity score matching (PSM), which ensures reliable comparisons between cancer and control groups. We employed Univariate Naïve Bayes, L2-regularized Support Vector Classifier (SVC), Principal Component Analysis (PCA), and feature engineering techniques to refine and select the most informative features. Our best-performing feature set comprised 11 biomarkers, including 9 metabolites (SM(OH) C22:2, SM C18:0, C0, C3OH, C14:2OH, C16:2OH, LysoPC a C18:1, PC aa C36:0 and Asparagine), a metabolite ratio (Kynurenine-to-Tryptophan), and 1 demographic variable (Age), achieving an area under the ROC curve (AUC) of 98%. These results demonstrate the potential for a robust, cost-effective, and non-invasive breast cancer screening and diagnostic tool, offering significant clinical value for early detection and personalized patient management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsBiomarkers, TumorEarly Detection of CancerMetabolomicsHumansFemaleMiddle AgedAdultAgedPrincipal Component AnalysisBayes TheoremCase-Control Studies

Stichwörter der Autor:innen

biomarkersbreast cancerearly detectionmachine learningmetabolomic profilingscreening

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Analytics, Harrisburg University of Science and Technology, Harrisburg, PA 17101, USA.
  • BioMark Diagnostics Inc., Richmond, BC V6X 2W2, Canada.
  • Asper Clinical Research Institute, Winnipeg, MB R2H 2A6, Canada.
  • BioMark Diagnostic Solutions Inc., Quebec City, QC G1P 4P5, Canada.

ORCID-Profile: Bharadwaj Popuri, Paramjit S Tappia, Guoyu Huang, Jean-François Haince

Förderung

  • Biomark Diagnostics Inc. (Richmond, BC, Canada), Maunders-McNeil Foundation (Ed-monton, AB, Canada)
  • BioMark Diagnostics Inc.

Zitieren

APA

Vaida, M., Arumalla, K. K., Tatikonda, P. K., Popuri, B., Bux, R. A., Tappia, P. S., Huang, G., Haince, J. F., & Ford, W. R. (2024). Identification of a Novel Biomarker Panel for Breast Cancer Screening. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252111835

Vancouver

Vaida M, Arumalla KK, Tatikonda PK, Popuri B, Bux RA, Tappia PS, et al. Identification of a Novel Biomarker Panel for Breast Cancer Screening. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252111835

BibTeX
@article{Vaida2024,
  author = {Vaida, Maria and Arumalla, Kamala K and Tatikonda, Pavan Kumar and Popuri, Bharadwaj and Bux, Rashid A and Tappia, Paramjit S and Huang, Guoyu and Haince, Jean-François and Ford, W Randolph},
  title = {Identification of a Novel Biomarker Panel for Breast Cancer Screening},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252111835}
}
Kostenlos starten →